Home / Community / News / News

News

10/23/2017 - 12:23pm

A new literature review suggests meta-analysis of cognitive studies in DM1 is both feasible and can inform understanding of disease mechanisms and patient management.

10/23/2017 - 12:20pm

It would be easy to conclude that insulin resistance and diabetes in myotonic dystrophy is a product of mis-splicing of INSR transcripts—but is that the full story?

10/23/2017 - 12:15pm

Toxic RNA-mediated mis-splicing and Repeat-Associated Non-AUG (RAN) translation proteins are impacted by free MBNL1 levels and contribute towards CNS pathogenesis in DM2.

09/26/2017 - 3:29pm

AMO Pharma released interim results for a Phase 2a safety and toxicity study of Tideglusib (also known as AMO-02) for adolescents and adults with congenital myotonic dystrophy.

09/18/2017 - 11:00am

New data is available on the frequency, progression and treatment of GI symptoms in DM1 and DM2.

Partners

© Myotonic Dystrophy Foundation. All rights reserved.